Jill Sloper is a distinguished Partner at Nelson Mullins Riley & Scarborough LLP, where she leverages her extensive expertise in intellectual property law to serve clients in the dynamic fields of biotechnology, pharmaceuticals, and life sciences. With a specialized focus on microbiology and immunology, Jill...
Jill Sloper is a distinguished Partner at Nelson Mullins Riley & Scarborough LLP, where she leverages her extensive expertise in intellectual property law to serve clients in the dynamic fields of biotechnology, pharmaceuticals, and life sciences. With a specialized focus on microbiology and immunology, Jill has built a reputation for her adept handling of complex patent preparation and prosecution processes. Her comprehensive understanding of the nuances involved in patent law allows her to provide invaluable insights into validity and infringement opinions, ensuring her clients navigate the intricacies of intellectual property with confidence.
Currently, Jill is engaged in several key projects that underscore her commitment to advancing innovation in biomedical technologies. She plays a pivotal role in conducting thorough intellectual property due diligence, enabling clients to make informed decisions regarding their research and development initiatives. Additionally, her expertise in freedom to operate analyses helps clients identify potential risks and opportunities in their product development pathways. Jill's proficiency in handling oppositions further solidifies her position as a trusted advisor in the industry.
As a registered patent attorney, Jill is well-versed in the complexities of patent term adjustments (PTA) and prosecution strategies, making her a sought-after resource for clients seeking to optimize their intellectual property portfolios. Her legal writing skills and strategic approach to intellectual property issues empower her clients to protect their innovations effectively. Through her work, Jill Sloper exemplifies a commitment to excellence in the legal landscape, driving forward the interests of her clients in the ever-evolving life sciences sector.
